NCI is implementing a less draconian formula for increasing the core grants of newer cancer centers.
The plan, which was unveiled at the Dec. 1 joint meeting of the Board of Scientific Advisors and the National Cancer Advisory Board, seeks to correct an acknowledged inequity: by virtue of being in the NCI program longer, more established cancer centers had more incremental increases, thus amassing larger core grants.
In a unanimous vote, BSA asked for some refinements to the plan, but seemed to be fine with its main features.
An earlier version of the plan called for fundamental changes in the funding formula, which—according to NCI modeling—would have reduced the core grants of some of the older, larger cancer centers and gave these funds to the newer centers.
| ||Capitol Hill |
NIH Looks For $1-2 Billion Raise in FY 2016
As Congress Approaches Another Deadline
NIH is slated to receive a $2 billion increase under the Senate appropriations bill, but only $1.1 billion under the House plan for the current 2016 fiscal year.
The Senate version would bring NIH finding up to $32 billion, with NCI receiving $5.204 billion. The House version would total just above $31 billion for NIH, including $5.081 billion for NCI.
Both chambers of Congress are setting aside $200 million for the Precision Medicine Initiative, which would include $70 million for NCI.
|Guest Editorial |
The Academic Difference
By George J. Weiner
Academic cancer centers have a major and unique role to play in enhancing cancer research, clinical care and education. This role will increase in value as our understanding of the complexity of cancer grows and is applied to care of patients.
Academic cancer centers leverage synergies among these various missions, with the result being a positive impact on patient health and the economy at the local, regional and national levels. Accelerating progress in cancer medicine is dependent on the success of academic cancer centers and development of new models of collaboration between academic cancer centers and community oncology.
|ACS and ASCO Jointly Publish Breast Cancer Survivorship Guideline for Primary Physicians|
The American Society for Clinical Oncology and the American Cancer Society published a joint guideline for primary care physicians on managing the long-term care of breast cancer survivors, recommending regular surveillance for recurrence, but not performing laboratory or imaging tests in patients not displaying symptoms.
- Carlos Rodriguez-Galindo to lead St. Jude’s international outreach
- Daniel Simon named president of UH Case Medical Center
- Terrill Jordan named president and CEO of Regional Cancer Care Associates
- Gustave Roussy institute recruiting young doctors
- Baylor to collaborate with Biocept on blood-based cancer tests
|Drugs and Targets|
- FDA grants accelerated approval to Alecensa for ALK-positive NSCLC patients
- FDA approves Vistogard for emergency treatment of certain chemotherapy overdoses
- FDA clears cooling cap for preventing hair loss during chemotherapy
- EMA grants orphan designation ot Debio 1143
- Amgen submits expanded application for Kyprolis in the EU
- AstraZeneca and Voluntis to test digital support service in ovarian cancer trials
- Eli Lilly and Merck to collaborate on abemaciclib-Keytruda phase I trial